{"id":364,"date":"2024-12-06T17:40:36","date_gmt":"2024-12-06T17:40:36","guid":{"rendered":"https:\/\/forward-tx.com\/?p=364"},"modified":"2024-12-06T18:03:45","modified_gmt":"2024-12-06T18:03:45","slug":"vincent-aurentz-joins-forward-therapeutics-board-of-directors","status":"publish","type":"post","link":"https:\/\/forward-tx.com\/vincent-aurentz-joins-forward-therapeutics-board-of-directors\/","title":{"rendered":"Vincent Aurentz Joins Forward Therapeutics’ Board of Directors"},"content":{"rendered":"\n
Palm Beach Gardens, FL, December 6, 2024\u2014Forward Therapeutics, Inc., a pioneering biopharmaceutical company committed to transforming the treatment of chronic inflammatory disorders, today announced the appointment of Vincent Aurentz to its board of directors.<\/p>\n\n\n\n
Mr. Aurentz brings extensive strategic expertise and business leadership, developed over more than 35 years in the biopharmaceutical industry. Notably, he served as Executive Vice President (EVP) and Chief Business Officer (CBO) at Arena Pharmaceuticals, where he played a pivotal role in shaping corporate strategy and business development. His leadership efforts culminated in Arena\u2019s acquisition by Pfizer for $6.7 billion. Mr. Aurentz also played a significant role in the formation of Arena\u2019s spinout, Longboard Therapeutics, which was recently acquired by Lundbeck for approximately $2.6 billion. He served on Longboard\u2019s board, further contributing to its strategic growth and success.<\/p>\n\n\n\n